Protagonist Therapeutics Inc. (PTGX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV.
Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement
Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis and other inflammatory disorders, with phase 2b study initiation planned for Q1 2027.
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to a loss of $0.55 per share a year ago.
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal
Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, leveraging major pharma partners for commercialization without heavy infrastructure costs. ICOTYDE's FDA approval and rusfertide's Priority Review position PTGX for milestone payments, high-margin royalties, and a capital-light revenue model. PTGX maintains a strong balance sheet with $620M+ cash, a funding runway through 2028, and episodic profitability, reducing financing risk.
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
